Greenwich LifeSciences Inc, a Phase 3 biotech developing immunotherapies for breast cancer, has filed Amendment No. 3 to Form S-1 Registration Statement on September 9, 2020 with the U.S. Securities and Exchange Commission to decrease the proposed IPO size to $18 million IPO.
The company now plans to raise $18 million by offering 2.9 million shares at the price range of $5.75 to $6.75. Previously the company proposed to offer 2.7 million shares at the price range of $7.50 to $8.50. The Stafford, Texas-based company was founded in 2006 is planning to commence a Phase 3 trial in 2020.
The company is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery.
It plans to list on the Nasdaq Capital Market under the symbol “GLSI.” Aegis Capital Corp. is the underwriter of the IPO.
The company engages Sheppard, Mullin, Richter & Hampton LLP as US Securities Counsel, and MaloneBailey, LLP as Independent Auditor.
#ipo #nasdaq #GreenwichLifeSciences #breastcanserprevention #healthcare
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
